U.S. Stem Cell Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
15
- Stock Symbol
-
USRM
- Investments
-
1
U.S. Stem Cell General Information
Description
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Contact Information
Website
www.us-stemcell.comCorporate Office
- 1560 Sawgrass Corporate Parkway
- 4th Floor
- Sunrise, FL 33323
- United States
Corporate Office
- 1560 Sawgrass Corporate Parkway
- 4th Floor
- Sunrise, FL 33323
- United States
U.S. Stem Cell Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 415K |
U.S. Stem Cell Financials Summary
As of 31-Dec-2022, U.S. Stem Cell has a trailing 12-month revenue of $82K.
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 11,769 | 11,769 | 10,713 | 11,164 |
| Revenue | 82 | 82 | 201 | 277 |
| EBITDA | (2,168) | (2,168) | (2,287) | (2,402) |
| Net Income | (2,858) | (2,858) | (3,287) | (2,890) |
| Total Assets | 68 | 68 | 51 | 88 |
| Total Debt | 8,947 | 8,947 | 8,016 | 7,485 |
U.S. Stem Cell Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
U.S. Stem Cell Comparisons
Industry
Financing
Details
U.S. Stem Cell Competitors (26)
One of U.S. Stem Cell’s 26 competitors is NOVADIP, a Venture Capital-Backed company based in Mont-Saint-Guibert, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NOVADIP | Venture Capital-Backed | Mont-Saint-Guibert, Belgium | ||||
| Orbsen Therapeutics | Formerly PE-Backed | Galway, Ireland | ||||
| BioCardia | Formerly VC-backed | Sunnyvale, CA | ||||
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Regenerative Medical Solutions | Venture Capital-Backed | Madison, WI |
U.S. Stem Cell Patents
U.S. Stem Cell Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20050171578-A1 | Method of enhancing myogenesis by electrical stimulation | Active | 13-Jun-2001 | ||
| US-7483749-B2 | Method of enhancing myogenesis by electrical stimulation | Inactive | 13-Jun-2001 | ||
| US-7341062-B2 | Method of providing a dynamic cellular cardiac support | Inactive | 12-Mar-2001 | ||
| AU-2001255850-A1 | Catheter assembly for treating ischemic tissue | Inactive | 14-Dec-2000 | ||
| AU-2001259073-A1 | Catheter assembly for treating ischemic tissue | Inactive | 14-Dec-2000 | A61M25/04 |
U.S. Stem Cell Signals
U.S. Stem Cell Acquisitions (1)
U.S. Stem Cell’s most recent deal was a Merger/Acquisition with Pavillion Scientific. The deal was made on 03-Jun-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pavillion Scientific | 03-Jun-2015 | Merger/Acquisition | Other Devices and Supplies |
U.S. Stem Cell ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Services
Subindustry
Rank
Percentile
U.S. Stem Cell FAQs
-
When was U.S. Stem Cell founded?
U.S. Stem Cell was founded in 1999.
-
Where is U.S. Stem Cell headquartered?
U.S. Stem Cell is headquartered in Sunrise, FL.
-
What is the size of U.S. Stem Cell?
U.S. Stem Cell has 15 total employees.
-
What industry is U.S. Stem Cell in?
U.S. Stem Cell’s primary industry is Biotechnology.
-
Is U.S. Stem Cell a private or public company?
U.S. Stem Cell is a Public company.
-
What is U.S. Stem Cell’s stock symbol?
The ticker symbol for U.S. Stem Cell is USRM.
-
What is U.S. Stem Cell’s current revenue?
The trailing twelve month revenue for U.S. Stem Cell is $82K.
-
Who are U.S. Stem Cell’s competitors?
NOVADIP, Orbsen Therapeutics, BioCardia, Mesoblast, and Regenerative Medical Solutions are some of the 26 competitors of U.S. Stem Cell.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process